- Home
- DNA vs CSTL Comparison
DNA vs CSTL Comparison
Compare DNA & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNA
- CSTL
- Stock Information
- Founded
- DNA 2008
- CSTL 2007
- Country
- DNA United States
- CSTL United States
- Employees
- DNA N/A
- CSTL N/A
- Industry
- DNA Biotechnology: Biological Products (No Diagnostic Substances)
- CSTL Medical Specialities
- Sector
- DNA Health Care
- CSTL Health Care
- Exchange
- DNA Nasdaq
- CSTL Nasdaq
- Market Cap
- DNA 658.5M
- CSTL 561.9M
- IPO Year
- DNA N/A
- CSTL 2019
- Fundamental
- Price
- DNA $9.42
- CSTL $18.82
- Analyst Decision
- DNA Sell
- CSTL Strong Buy
- Analyst Count
- DNA 3
- CSTL 6
- Target Price
- DNA $9.67
- CSTL $37.67
- AVG Volume (30 Days)
- DNA 1.6M
- CSTL 425.8K
- Earning Date
- DNA 08-07-2025
- CSTL 08-04-2025
- Dividend Yield
- DNA N/A
- CSTL N/A
- EPS Growth
- DNA N/A
- CSTL N/A
- EPS
- DNA N/A
- CSTL N/A
- Revenue
- DNA $237,417,000.00
- CSTL $347,083,000.00
- Revenue This Year
- DNA N/A
- CSTL N/A
- Revenue Next Year
- DNA $15.91
- CSTL $1.36
- P/E Ratio
- DNA N/A
- CSTL N/A
- Revenue Growth
- DNA 13.76
- CSTL 38.43
- 52 Week Low
- DNA $5.00
- CSTL $15.45
- 52 Week High
- DNA $16.85
- CSTL $35.84
- Technical
- Relative Strength Index (RSI)
- DNA 51.44
- CSTL 53.48
- Support Level
- DNA $9.75
- CSTL $19.29
- Resistance Level
- DNA $13.33
- CSTL $20.26
- Average True Range (ATR)
- DNA 0.87
- CSTL 0.60
- MACD
- DNA -0.18
- CSTL -0.10
- Stochastic Oscillator
- DNA 28.59
- CSTL 37.64
About DNA Ginkgo Bioworks Holdings Inc.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.